Details
This analysis examined the association between use of proton pump inhibitors (PPI) versus famotidine and development of two COVID-19 related outcomes: hospitalization with COVID-19 infection, and severe clinical course of COVID-19 infection (defined as requiring a mechanical ventilation or intensive care unit (ICU) care, or inpatient death during a COVID-19 hospitalization) among patients with gastroesophageal reflux disease (GERD) in the Sentinel Distributed Database (SDD). This is a follow up to a previous analysis. This updated analysis includes an extended study period, an increased number of Data Partners, and the incorporation of new analytic methods. We distributed this request to 12 Sentinel Data Partners on August 12, 2024. We included data from six Data Partners where the propensity score models converged. This analysis includes two reports:
- Report 1: The study period includes data from April 1, 2020 to January 31, 2024. This report contains data from five Sentinel Data Partners and does not include patients with Medicare coverage.
- Report 2: The study period includes data from April 1, 2020 to June 30, 2023. This report contains data from patients with Medicare coverage.
The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.